FDA approves Mirada Medical's Simplicit90Y Dosimetry software

Simplicit90Y facilitates the design of more personalized planning for radioembolization treatments

February 25, 2019
by John R. Fischer , Staff Reporter
The FDA has given thumbs-up to Mirada Medical for the launch of its Simplicit90Y dosimetry software across the U.S.

Designed in collaboration with BTG for personalized treatment of patients with liver cancer, the solution speeds up dosimetry planning and improves workflow of Y90 TransArterial Radioembolization, a form of treatment in which doctors use a catheter to deliver tiny glass spheres of Yttrium-90 (Y90) radiation directly into cancer cells of the liver where they become permanently lodged and continued to deliver radiation to the tumor over the course of several weeks.

"TheraSphere Y90 glass microspheres are specifically engineered to deliver high doses of radiation to liver tumors while sparing normal tissue," Mirada Medical told HCB News. "The result is a powerful, targeted and well-tolerated therapy that may lead to patients becoming eligible for curative therapies."

Performing a TheraSphere procedure requires merging data sets from multiple types of imaging modalities to develop a treatment plan and calculate the appropriate dose of TheraSphere. Simplicit90Y does this through its digital processing, review and reporting of medical images, creating a streamlined, single interface in which users can incorporate multimodal images, and use automated and semi-automated tools for segmentation, manipulate data and expedite analysis.

It also offers data display, quality control, image manipulation and quantification analysis, all of which help to standardize and create reproducible dosimetry planning for more consistent and personalized treatment based on an individual patient's needs, as well as post-treatment validation for the assessment of the absorbed dose delivered to the patient.

"The software should be of interest to providers looking to optimize radioembolization therapy," said Mirada Medical. "It allows them to offer patients a personalized treatment, but can also help improve the efficiency and consistency of treatment."

A recent study found radioembolization to be an effective option for treating children with hard-to-reach liver cancer that is resistant to chemotherapy and cannot be surgically removed to help improve survival time.

In the U.S., TheraSphere is approved under a Humanitarian Device Exemption (HDE) for use in radiation treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable hepatocellular carcinoma (HCC) who can have placement of appropriately positioned hepatic arterial catheters. The device is also indicated for HCC patients with partial or branch portal vein thrombosis/occlusion, when clinical evaluation warrants the treatment. The effectiveness of this device for this use has not been demonstrated.

The system is cleared for use in Canada and is CE marked. It is approved under a Humanitarian Device Exemption in the U.S. for use in radiation treatment; as a neoadjuvant to surgery or transplants in patients with unresectable hepatocellular carcinoma (HCC), who are approved for placement of appropriately positioned hepatic arterial catheters; and for HCC patients with partial or branch portal vein thrombosis, when warranted by clinical evaluation. The effectiveness of the device for this last use has not been demonstrated.

BTG plans to showcase it from March 23-28 at the Society of Interventional Radiology (SIR) congress in Austin.

More Rad Oncology

Fivefold difference found in Medicaid reimbursements for radiotherapy

Trends in radiation oncology workforce potentially threaten rural patients, says study

Varian showcases first preclinical findings of Flash therapy trial

Female oncologists submit fewer charges, paid less than male

Four considerations before embarking on a carbon therapy center

Q&A with Scott Warwick, executive director of the National Association for Proton Therapy

New approach identifies lung cancer patients most likely to respond to chemotherapy

Aussies and Americans develop 3D models for assessing impacts of radiotherapy

Law in Ontario prevents cremation of brachytherapy patients

IBA tech plays first-time role in flash therapy demonstration